Bristol UFT oral anticancer agent NDA filing projected for 1998 under licensing agreement with Taiho.
Executive Summary
BRISTOL PROJECTS 1998 NDA FILING FOR UFT FOR COLORECTAL CANCER under a licensing agreement with Taiho Pharmaceutical announced May 10. Under the agreement, Bristol-Myers Squibb will complete Phase III studies of the oral anticancer agent for the colorectal cancer indication and other indications which have not been identified. Bristol will have exclusive rights to the product throughout the world, except in Japan, Spain and several Asia-Pacific countries.